PubRank

SORAVE - Sorafenib and Everolimus in Solid Tumors (SORAVE)

Clinical Trial ID NCT00933777

PubWeight™ 1.79‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00933777

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 30.94
2 Multidisciplinary management of lung cancer. N Engl J Med 2004 7.13
3 Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008 5.98
4 Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008 5.28
5 Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2004 5.12
6 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 4.67
7 Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 2.51
8 Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005 1.81
9 Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol 2007 0.93
10 Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag 2014 0.93
11 Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One 2013 0.90
12 Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol 2003 0.87
Next 100